REDHILL BIOPHAR/S (NASDAQ:RDHL) PT Set at $16.00 by HC Wainwright

HC Wainwright set a $16.00 price objective on REDHILL BIOPHAR/S (NASDAQ:RDHL) in a report issued on Monday morning, TipRanks reports. The firm currently has a buy rating on the biotechnology company’s stock.

Several other research firms have also commented on RDHL. WBB Securities upgraded REDHILL BIOPHAR/S from a buy rating to a strong-buy rating and set a $17.00 price target on the stock in a report on Friday, July 12th. Ascendiant Capital Markets set a $23.00 price target on REDHILL BIOPHAR/S and gave the stock a buy rating in a report on Monday, July 8th. ValuEngine upgraded REDHILL BIOPHAR/S from a sell rating to a hold rating in a report on Monday, July 22nd. Finally, Zacks Investment Research upgraded REDHILL BIOPHAR/S from a hold rating to a buy rating and set a $8.00 price target on the stock in a report on Friday, October 4th. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $17.60.

NASDAQ RDHL opened at $6.25 on Monday. REDHILL BIOPHAR/S has a 52 week low of $5.13 and a 52 week high of $9.57. The company has a quick ratio of 2.71, a current ratio of 2.84 and a debt-to-equity ratio of 0.10. The business’s fifty day simple moving average is $7.11 and its 200-day simple moving average is $7.33. The firm has a market cap of $144.78 million, a PE ratio of -3.68 and a beta of 1.26.

REDHILL BIOPHAR/S (NASDAQ:RDHL) last posted its quarterly earnings results on Tuesday, July 23rd. The biotechnology company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.06). REDHILL BIOPHAR/S had a negative return on equity of 93.55% and a negative net margin of 561.47%. The company had revenue of $1.56 million for the quarter, compared to analysts’ expectations of $2.23 million. Research analysts expect that REDHILL BIOPHAR/S will post -1.43 EPS for the current year.

Institutional investors and hedge funds have recently modified their holdings of the stock. CLARET ASSET MANAGEMENT Corp grew its stake in REDHILL BIOPHAR/S by 22.1% in the 3rd quarter. CLARET ASSET MANAGEMENT Corp now owns 75,102 shares of the biotechnology company’s stock valued at $529,000 after acquiring an additional 13,600 shares during the period. Jane Street Group LLC acquired a new stake in REDHILL BIOPHAR/S in the 2nd quarter valued at $384,000. ETF Managers Group LLC grew its stake in REDHILL BIOPHAR/S by 10.7% in the 2nd quarter. ETF Managers Group LLC now owns 46,255 shares of the biotechnology company’s stock valued at $299,000 after acquiring an additional 4,453 shares during the period. Ibex Investors LLC grew its stake in REDHILL BIOPHAR/S by 91.3% in the 2nd quarter. Ibex Investors LLC now owns 1,867,000 shares of the biotechnology company’s stock valued at $12,136,000 after acquiring an additional 891,072 shares during the period. Finally, Sanders Morris Harris LLC acquired a new stake in REDHILL BIOPHAR/S in the 2nd quarter valued at $330,000. Hedge funds and other institutional investors own 37.75% of the company’s stock.

About REDHILL BIOPHAR/S

RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The company's clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohn's disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors.

Read More: How do buyers and sellers choose a strike price?

Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.